PrimeC normalizes iron biomarkers in Phase 2b ALS trial

PrimeC normalizes iron biomarkers in Phase 2b ALS trial

One year of treatment with the experimental oral therapy PrimeC led to improved iron accumulation in people with amyotrophic lateral sclerosis (ALS), according to new clinical trial data announced by PrimeC’s developer, Neurosense Therapeutics. Previous results showed that people who received PrimeC for one year experienced significantly slower…

Oh, the hugs I’ve missed as times have changed

“I really want to go to your performance,” my husband, Todd, told our daughter, Sara, who was starting a weeklong intensive with Eisenhower Dance Detroit that will culminate in a performance Saturday. “It’s just too hard to get out, and I don’t want to sit in the theater with…

Revir raises $30M to develop oral RNA-targeted therapies

The biotechnology company Revir Therapeutics has raised $30 million in funding to advance the development of oral genetic therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. This Series A financing was led by the healthcare-focused venture capital firm Lapam Capital. Revir will use the proceeds to…